BIM
CBAY

BlackRock Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

BlackRock Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$7K Hold
3,841
– – ﹤0.01% 3705
2016
Q3 		$7K Buy
3,841
+275
+8% +$547 ﹤0.01% 3713
2016
Q2 		$6K Hold
3,566
– – ﹤0.01% 3824
2016
Q1 		$5K Hold
3,566
– – ﹤0.01% 3822
2015
Q4 		$6K Buy
3,566
+415
+13% +$677 ﹤0.01% 3835
2015
Q3 		$6K Buy
3,151
+912
+41% +$2.48K ﹤0.01% 3885
2015
Q2 		$6K Buy
+2,239
New +$9.2K ﹤0.01% 3913

Other funds holding CBAY

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock Investment Management's CBAY Position: Q4 2016 in Review

BlackRock Investment Management held its Cymabay Therapeutics (CBAY) position steady in Q4 2016 at 3,841 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

BlackRock Investment Management first reported a position in CBAY in Q2 2015 and has held it in 7 quarters since. 27 funds tracked by Wall St. Rank hold CBAY as of Q4 2016.

  • BlackRock Investment Management held 3,841 shares of Cymabay Therapeutics worth $7K as of Q4 2016.
  • BlackRock Investment Management left its Cymabay Therapeutics share count unchanged in Q4 2016.
  • Cymabay Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3705 holding.
  • BlackRock Investment Management first reported a position in Cymabay Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • 27 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.